Horizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
|
|
- Bernice Kelly
- 5 years ago
- Views:
Transcription
1 Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises the interleukin 17A (IL-17A) receptor. It is intended for the treatment of active and progressive psoriatic arthritis (PsA) after failure of conventional disease modifying anti-rheumatic drugs (DMARDs). This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or i i i PsA is a chronic inflammatory joint disease associated with psoriasis of the skin or nails. The diagnosis of PsA tends to occur within 10 years of a psoriasis diagnosis. PsA leads to stiffness, pain, swelling and tenderness of the joints and surrounding ligaments and tendons. The most commonly affected areas include the small joints of the hands and feet, but it may also involve other larger joints such as hips, knees and spine. PsA can significantly affect ability to work and to carry out daily tasks, which can have a substantial impact on quality of life. An estimated 5-10% of people with psoriasis and 25-40% of people with PsA have severe arthritis with progressive joint lesions. Joint damage has been shown radiologically in up to 47% of people with PsA at a median interval of 2 years. In , there were 6,801 hospital admissions for PsA (L40.5) in England and Wales, accounting for 5,046 bed days and 6,967 finished consultant episodes. DMARDs are usually administered within three months of diagnosis to stabilise joint function, either as monotherapy or in combination with biologic agents. TNF-α inhibitors such as etanercept, infliximab, adalimumab and golimumab are administered when there has been no response to adequate trials of at least two DMARDs. Secukinumab is currently in a phase III clinical trial comparing its effect on clinically important improvements in arthritis outcomes against placebo in patients with active and progressive PsA who have responded inadequately to previous therapy with DMARDs. Secukinumab is currently also in a phase II extension trial assessing safety and tolerability. Both trials were expected to complete in July 2012 and November 2012 respectively. This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. NIHR Horizon Scanning Centre, University of Birmingham nihrhsc@contacts.bham.ac.uk Web:
2 TARGET GROUP Psoriatic arthritis (PsA): active and progressive patients who have responded inadequately to previous therapy with disease modifying anti-rheumatic drugs (DMARDs). TECHNOLOGY DESCRIPTION Secukinumab (AIN-457, KB-03303A) is a high-affinity fully human monoclonal antibody which specifically antagonises the interleukin 17A (IL-17A) receptor. IL-17A is a proinflammatory cytokine secreted exclusively by activated T-cells and is thought to be involved in autoimmunity. Secukinumab is intended for the treatment of active and progressive PsA after failure of conventional DMARDs. Secukinumab is administered by intravenous (IV) infusion as 3 loading doses of 10mg/kg, followed by 75mg or 150mg subcutaneous (SC) injections every 4 weeks. Secukinumab is currently in the following phases of clinical trials for the stated indications: Phase III Rheumatoid arthritis. Ankylosing spondylitis (treatment experienced patients). Plaque psoriasis. Phase II Behcet's disease. Uveitis (adjunctive treatment). Asthma. Multiple sclerosis (relapsing-remitting). Polymyalgia rheumatica. Xerophthalmia. INNOVATION and/or ADVANTAGES If licensed, secukinumab will become the first available interleukin 17A (IL-17A) receptor antagonist and may provide an additional treatment option for this patient group. DEVELOPER Novartis General Medicines. AVAILABILITY, LAUNCH OR MARKETING Currently in phase III clinical trials. PATIENT GROUP BACKGROUND PsA is a chronic inflammatory joint disease associated with psoriasis of the skin or nails. The diagnosis of PsA tends to occur within 10 years of diagnosis with psoriasis 1 and leads to 2
3 stiffness, pain, swelling and tenderness of the joints and surrounding ligaments and tendons. The most commonly affected areas include the small joints of the hands and feet, but it may also involve other larger joints such as hips, knees and spine 2. PsA has a chronic relapsing course, characterised by flares and remissions, which may be life-long 3. Although the cause of psoriasis and its associated arthritis is not fully understood, evidence suggests that it is a T-cell mediated disease, most likely auto-immune in origin, with a strong genetic component 4. NHS or GOVERNMENT PRIORITY AREA This topic is relevant to: The Musculoskeletal Services Framework (2006). CLINICAL NEED and BURDEN OF DISEASE The prevalence of psoriasis in the UK population is estimated at between 1.5-3% 1,2. The prevalence of inflammatory arthritis in people with psoriasis is estimated at 30% 1, however a prevalence of 50% has been recorded in some population studies 5. An estimated 5-10% of people with psoriasis and 25-40% of people with PsA have severe arthritis with progressive joint lesions 6. Joint damage has been shown radiologically in up to 47% of people with PsA at a median interval of 2 years 1. PsA has an equal gender distribution and characteristically develops in those aged years. It is estimated there are 60,353 people in England with PsA, of whom 2.4% are potentially eligible to receive treatment with biologics 7. There is currently no reliable, specific information available for how many people are intolerant or have an inadequate response to tumour necrosis factor alpha (TNF-α) inhibitors. PsA can significantly affect the ability to work and to carry out daily tasks, and can have a substantial impact on quality of life 1. Several comorbid conditions are also associated with PsA, including psychological and cardiovascular disease, and their management has a major impact on the economic burden associated with PsA 5. People with PsA have a 60% higher risk of mortality 1 and their life expectancy is estimated to be reduced by approximately 3 years 8. In , there were 6,801 hospital admissions for PsA (L40.5) in England and Wales, accounting for 5,046 bed days and 6,967 finished consultant episodes 9. PATIENT PATHWAY RELEVANT GUIDANCE NICE Guidance NICE technology appraisal. Golimumab for the treatment of psoriatic arthritis (TA220). April NICE technology appraisal. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199). August Other Guidance Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of psoriasis and psoriatic arthritis in adults British Society of Rheumatology. Guideline for anti-tnf-a therapy in psoriatic arthritis
4 EXISTING COMPARATORS and TREATMENTS The clinical management of PsA aims to suppress joint, tendon and entheseal inflammation 4, and reduce functional limitations and joint damage. This includes a range of physical therapy and pharmacological treatments such as 1,3,10 : Non-biologic therapies Analgesics. Corticosteroids limited role in PsA 5. Non-steroidal anti-inflammatory drugs (NSAIDs). DMARDs, including methotrexate (MTX) a, sulfasalazine, leflunomide, gold salts (very rarely used), and anti-malarials (very rarely used). Usually administered within three months of diagnosis to stabilise joint function, either as monotherapy or in combination with biologic agents. Biologic therapies TNF-α inhibitors such as etanercept, infliximab, adalimumab and golimumab. Should be administered when there has been no response to adequate trials of at least two DMARDs administered either individually or in combination. EFFICACY and SAFETY Trial FUTURE 1, NCT ; secukinumab vs placebo; phase III. NCT , secukinumab vs placebo; phase II. NCT , secukinumab; phase II extension. Sponsor Novartis pharmaceuticals. Novartis pharmaceuticals. Novartis pharmaceuticals. Status Ongoing. Complete but unpublished. Ongoing. Source of information Trial registry 12, manufacturer. Trial registry 13, manufacturer. Trial registry 14, manufacturer. Location EU (incl UK), USA, Canada and other countries. Germany, Netherlands and UK. Germany, Netherlands and UK. Design Participants Randomised, placebocontrolled. n=600 (planned); aged 18 years; diagnosis of PsA classified by CASPAR criteria b ; moderate to severe PsA; symptoms 6 months; 3/78 tender joints and 3/76 swollen joints; rheumatoid factor and anti-ccp antibodies negative; diagnosis of active plaque psoriasis. Randomised, placebocontrolled. n=42; aged 18 years; diagnosis of PsA; Non-randomised, singlearm. n=42 (planned); aged 18 years; diagnosis of PsA; completed study NCT a Expert opinion suggests MTX is the mainstay of existing treatments in those who reach hospital care but experience suggests this alone is inadequate in 50% of cases seen. If TNF-α inhibitors are added, a further 30% of patients do well, leaving 20% of patients for whom therapy that exploits a different mode of action is appealing. b CASPAR criteria: classification criteria for psoriatic arthritis. 4
5 Schedule Randomised to secukinumab 10mg/kg IV at baseline, week 2 and week 4, then secukinumab 75mg SC starting at week 8 and every 4 weeks therafter; or secukinumab 10mg/kg IV at baseline, week 2 and week 4, then secukinumab 150mg SC starting at week 8 and every 4 weeks thereafter; or placebo IV at baseline, week 2 and week 4, then placebo SC starting at week 8 and again at week 12. Randomised to secukinumab 10mg/kg or placebo, both IV, at baseline and week 3. Secukinumab 3mg/kg IV every 4 weeks. At week 16, participants classified as responders or non-responders. Subjects randomised to placebo at baseline then rerandomised at week 24 to receive either secukinumab 75mg or 150mg SC every 4 weeks. Follow-up Active treatment for 2 years. Primary outcome/s Secondary outcome/s ACR20 c response at 24 weeks in subgroup who are TNFα naïve. ACR20 response at week 24; HAQ-DI d at 24 weeks in TNFα naïve patients; van der Heijde modified total sharp score e in TNFα naïve patients; ACR70 at 12 months in TNFα naïve patients. Active treatment for 3 weeks, follow-up to week 24. ACR20 at week 6. ACR20, 50 and 70 up to week 24; PsARC f response up to 24 weeks; MASES g, SPARCC h and LDI i up to 24 weeks; AEs. Initial active treatment period of 24 weeks; further 6 months active treatment subject to risk/benefit decision. Safety and tolerability up to 64 weeks. Immunogenicity up to 64 weeks; total blood IL-17 concentration up to week 64; pharmacokinetics. c ACR: the American College of Rheumatology criteria are a core set of six outcome variables for the assessment of clinically important improvement: physical global assessment of disease activity; patient global assessment of overall wellbeing; functional ability; number of joints with active arthritis; number of joints with limited range of motion; and ESR. ACR20, ACR50 and ACR70 represent a 20%, 50% and 70% improvement in at least three response criteria (with no more than one response variable worse by greater than 30%). d Health Assessment Questionnaire Disability Index (HAQ-DI). e van der Heijde total modified Sharp score (SvH): radiographic scoring method used in rheumatology. f PsARC: Psoriatic arthritis response criteria (based on measures of tender and swollen joint counts, and physician's and patient s global assessment of disease activity). g MASES: Mastricht Ankylosing Spondylitis Enthesitis Score (calculated based on the presence or absence of tenderness at 13 sites). h SPARCC: Spondyloarthritis Research Consortium of Canada. Outcome measure that quantifies inflammation in vertebral bodies through the use of Magnetic Resonance Imaging. i LDI: Leeds Dactylitis Instrument (validated tool for assessing dactylitis in psoriatic disease) 5
6 Key results Adverse effects (AEs) Expected reporting date - - Primary completion date previously reported as July Previously reported as December Study completion date reported as November ESTIMATED COST and IMPACT COST The cost of secukinumab is not yet known. The cost of selected comparator treatments for PsA are summarised below: Drug Dose Annual cost 1,9. Adalimumab 40mg SC every 2 weeks. 9,295 Etanercept 25mg SC twice weekly, or 50mg once weekly. 9,295 Infliximab 5mg/kg IV at week 0, 2 and 6, then every 8 weeks. 13,428 for first year j. 10,910 for subsequent years. Golimumab 50mg SC once monthly. 9,295 IMPACT - SPECULATIVE Impact on Patients and Carers Reduced mortality/increased length of survival Reduced symptoms or disability Other: No impact identified Impact on Services Increased use of existing services: IV loading doses would require additional clinic time. Decreased use of existing services: Re-organisation of existing services Need for new services Other: None identified j Based on an adult weight of between 65 and 80kg. 6
7 Impact on Costs Increased drug treatment costs Reduced drug treatment costs Other increase in costs: Other reduction in costs: Other: uncertain unit cost compared to existing treatments. None identified Other Issues Clinical uncertainty or other research question identified: expert opinion suggests that improved disease control with any agent in PsA would also lead to less joint surgery, less hospital admission and improved quality of life and employability k. REFERENCES None identified 1 National Institute for Health and Clinical Excellence. Etanercept, infliximab and Adalimumab for the treatment of psoriatic arthritis (review). Technology appraisal TA199. London: NICE; August The Psoriasis Association. Psoriatic arthritis. May Accessed 17 October Kyle S, Chandler D, Griffiths CEM et al. Guideline for anti-tnf-a therapy in psoriatic arthritis. Rheumatology 2005;44: Griffiths CEM, Clark CM, Chalmers RJG et al. A systematic review of treatments for severe psoriasis. Health Technology Assessment 2000;4(40). 5 NIHR Horizon Scanning Centre. Ustekinumab (Stelara) for psoriatic arthritis with structural joint damage. Birmingham: NIHR HSC; September NIHR Horizon Scanning Centre. Certolizumab pegol (Cimzia) for psoriatic arthritis second line. Birmingham: NIHR HSC; September National Institute for Health and Clinical Excellence. Costing statement: Psoriatic arthritis golimumab. London: NICE; April Woolacott N, Bravo Vergel Y, Hawkins N et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2006;10:(31). 9 NHS. Hospital episode statistics. NHS England HES data National Institute for Health and Clinical Excellence. Golimumab for the treatment of psoriatic arthritis. Technology appraisal TA220. London: NICE; April Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults. National clinical guideline 121. Edinburgh: SIGN; October Clinicaltrials.gov. Efficacy at 24 weeks and long term safety, tolerability and efficacy up to 2 years of secukinumab (AIN457) in patients with active psoriatic arthritis (PsA) (FUTURE 1). Accessed 15 October Clinicaltrials.gov. Efficacy of AIN457 in adults (18-65 years) with psoriatic arthritis. Accessed 16 October Clinicaltrials.gov. Safety and tolerability of AIN457 in adults (18-65 Years) with psoriatic arthritis. Accessed 16 October k Expert opinion. 7
Certolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationHorizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716
Horizon Scanning Centre January 2013 Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716 This briefing is based on information available at the time of research and a limited literature search.
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationCertolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
NIHR Innovation Observatory Evidence Briefing: April 2017 Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112 LAY SUMMARY Plaque psoriasis is the most
More informationHorizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited
More informationPublic observer slides
Public observer slides Lead team presentation Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple
More informationapremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd.
apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd. 08 May 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationPsoriatic Arthritis- Second Line Treatments
Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationTechnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340
Ustekinumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationNIHR Innovation Observatory Evidence Briefing: November 2017
NIHR Innovation Observatory Evidence Briefing: November 2017 Upadacitinib for adults with moderate to severe active rheumatoid arthritis after conventional synthetic disease-modifying anti-rheumatic drugs
More informationcertolizumab pegol (Cimzia )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480
Tofacitinib for moderate to severeere rheumatoid arthritis Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480 NICE 2018. All rights reserved. Subject to Notice of rights
More informationSYNOPSIS. Issue Date: 17 Jan 2013
STELARA (ustekinumab) Clinical Study Report CNTO1275PSA3002 24-Week CSR SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research &
More informationPsoriatic Arthritis- Secondary Care
Psoriatic Arthritis- Secondary Care Our Psoriatic Arthritis: First Line Treatments information sheet gives information on the treatments that can be prescribed by a GP, or that might be prescribed if the
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationHorizon Scanning Centre March Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209
Horizon Scanning Centre March 2015 Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209 This briefing is based on information available at the time of research and a limited
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationRisankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis
NIHR Innovation Observatory Evidence Briefing: November 2017 Risankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis NIHRIO (HSRIC) ID: 9708 NICE ID: 9191 LAY SUMMARY Plaque
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationHorizon Scanning Research & Intelligence Centre. Baricitinib for moderate to severe rheumatoid arthritis. May 2015 SUMMARY NIHR HSRIC ID: 5270
May 2015 Horizon Scanning Research & Intelligence Centre Baricitinib for moderate to severe rheumatoid arthritis SUMMARY NIHR HSRIC ID: 5270 This briefing is based on information available at the time
More informationHorizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
More information3 rd Appraisal Committee meeting, 28 February 2017 Committee D
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple Technology Appraisal 3 rd Appraisal Committee
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationHorizon Scanning Centre November Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects
Horizon Scanning Centre November 2014 Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects SUMMARY NIHR HSC ID: 8515 This briefing is based on information
More informationScottish Medicines Consortium
Scottish Medicines Consortium etanercept 25mg vial of powder for subcutaneous injection (Enbrel ) (No. 212/05) Wyeth New indication: severe active ankylosing spondylitis inadequately controlled by conventional
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationScottish Medicines Consortium
Scottish Medicines Consortium abatacept, 250mg powder for concentrate for solution (Orencia ) No. (400/07) Bristol Myers Squibb Pharmaceuticals Ltd 10 August 2007 The Scottish Medicines Consortium has
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationInfliximab (Remicade) for paediatric ulcerative colitis - second line
Infliximab (Remicade) for paediatric ulcerative colitis - second line September 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationTechnology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta199
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta199 NICE 2018. All rights reserved. Subject
More informationSeronegative Arthritis. Dr Mary Gayed 25 th April 2018
Seronegative Arthritis Dr Mary Gayed 25 th April 2018 Overview Description of the conditions Discussion of symptoms & investigations that may be required Discussion of management and treatment Questions
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationHorizon Scanning Centre May Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524
Horizon Scanning Centre May 2014 Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524 This briefing is based on information available at the time of research and a limited literature
More informationNEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes Madrid, Spain,
More informationWhat is Cosentyx (secukinumab)?
What is Cosentyx (secukinumab)? Cosentyx is the first of a new class of medicines called interleukin- 17A (IL- 17A) inhibitors to be approved for the treatment of moderate- to- severe plaque psoriasis,
More informationAPC/DTC Briefing Document
Page 1 London New Drugs Group APC/DTC Briefing Document GOLIMUMAB Contents Summary 1 Background 5 Guidelines 5 Dosing information 5 Drug interactions 6 Clinical studies 6 Ankylosing spondylitis 6 Psoriatic
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationinfliximab, 100mg, powder for concentrate for solution for infusion (Inflectra ) SMC No. (1007/14) Hospira UK Ltd.
infliximab, 100mg, powder for concentrate for solution for infusion (Inflectra ) SMC No. (1007/14) Hospira UK Ltd. 07 November 2014 (Issued 06 March 2015) The Scottish Medicines Consortium (SMC) has completed
More informationOpinion 1 October 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2014 CIMZIA 200 mg, solution for subcutaneous injection 1 B/2 1 ml prefilled syringes with needle guard
More information1 Executive summary. Background
1 Executive summary Background Rheumatoid Arthritis (RA) is the most common inflammatory polyarthropathy in the UK affecting between.5% and 1% of the population. The mainstay of RA treatment interventions
More informationSingle Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis
Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationGolimumab, compared to placebo, significantly improved symptoms in adults with active nonradiographic
golimumab 50mg/0.5mL solution for injection in pre-filled pen or syringe and 100mg/mL solution for injection in pre-filled pen (Simponi ) SMC No. (1124/16) Merck Sharp & Dohme Limited 8 January 2016 The
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report November 2016 Drug Indication ustekinumab (Stelara) Injection The treatment of adult patients with active psoriatic arthritis alone or in combination with
More informationHorizon Scanning Centre January Apremilast for psoriasis SUMMARY NIHR HSC ID: 2652
Horizon Scanning Centre January 2013 Apremilast for psoriasis SUMMARY NIHR HSC ID: 2652 This briefing is based on information available at the time of research and a limited literature search. It is not
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET SIMPONI Solution for Injection in a pre-filled syringe Solution for Injection in a pre-filled pen, SmartJect NAME OF MEDICINE SIMPONI Solution for Injection in a pre-filled syringe
More informationA Patient s Guide to. Treatments for Psoriatic Arthritis
A Patient s Guide to Treatments for Psoriatic Arthritis Who should read this guide? This guide is aimed at people with psoriatic arthritis (abbreviated as PsA), or those who care for a person with this
More informationTechnology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195
More informationadalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott)
adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott) 08 March 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationHorizon Scanning Centre March Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468
Horizon Scanning Centre March 2014 Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468 This briefing is based on information available at the time
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationPediatric Use: Safety and effectiveness of Ustekinumab (STELARA ) in pediatric patients have not been evaluated.
Original Issue Date (Created): January 1, 2010 Most Recent Review Date (Revised): January 28, 2014 Effective Date: April 1, 2014 I. POLICY Preauthorization Requirements for Ustekinumab (STELARA ) Note:
More informationSwitching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence
Drugs R D (2017) 17:509 522 DOI 10.1007/s40268-017-0215-7 REVIEW ARTICLE Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence Luisa Costa 1 Carlo Perricone 2 Maria Sole
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationTechnology appraisal guidance Published: 26 January 2016 nice.org.uk/guidance/ta375
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed Technology
More informationScottish Medicines Consortium
Scottish Medicines Consortium infliximab 100mg powder for intravenous infusion (Remicade ) No. (364/07) Schering-Plough UK Ltd 6 April 2007 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPsoriatic arthritis FACTSHEET
1 What is psoriatic arthritis? Psoriatic arthritis (PsA) is a disease where joints around the body become inflamed and sore. It can make moving about difficult and painful. People who have PsA also have
More informationNational Institute for Health and Clinical Excellence SCOPE. Rheumatoid arthritis: the management and treatment of rheumatoid arthritis in adults
National Institute for Health and Clinical Excellence 1 Guideline title SCOPE Rheumatoid arthritis: the management and treatment of rheumatoid arthritis in adults 1.1 Short title Rheumatoid arthritis 2
More informationTechnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466
Baricitinib for moderate to severeere rheumatoid arthritis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466 NICE 2017. All rights reserved. Subject to Notice of rights
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationOverview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology
Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology Paediatric Rheumatology Expert Meeting, London 4 th December 29 Dr. Richard Veselý, Dr. Emma Sala Soriano Paediatric Investigation
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRERIBING COMMITTEE (JAPC) Derbyshire commissioning guidance on biologic drugs f the treatment of Rheumatoid arthritis with methotrexate This algithm is a tool to aid the implementation
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Community Plan Medical Benefit Drug Policy ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION Policy Number: CS2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationTechnology appraisal guidance Published: 22 February 2012 nice.org.uk/guidance/ta247
Tocilizumab for the treatment of rheumatoid arthritis Technology appraisal guidance Published: 22 February 2012 nice.org.uk/guidance/ta247 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationGender differences in effectiveness of treatment in rheumatic diseases
Gender differences in effectiveness of treatment in rheumatic diseases Irene van der Horst-Bruinsma Associate Professor Rheumatology Center of Excellence of Axial Spondyloarthritis ARC/VU University Medical
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationA. Kopchev, S.Monov, D. Kyurkchiev, I.Ivanova, T. Georgiev (UMHAT St. Ivan Rilski, Medical University - Sofia, Bulgaria)
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 6 Issue 7 July 2017 PP. 08-12 Vascular endothelial growth factor (VEGF), cartilage oligomeric
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationSIMPONI Solution for Injection in a pre-filled syringe Solution for Injection in a pre-filled pen, SmartJect
SIMPONI Solution for Injection in a pre-filled syringe Solution for Injection in a pre-filled pen, SmartJect PRODUCT INFORMATION NAME OF THE MEDICINE Golimumab (rmc) CAS Registry Number: 476181-74-5 DESCRIPTION
More informationTechnology appraisal guidance Published: 28 November 2018 nice.org.uk/guidance/ta547
Tofacitinib for moderately to severelyerely active ulcerative colitis Technology appraisal guidance Published: 28 November 2018 nice.org.uk/guidance/ta547 NICE 2019. All rights reserved. Subject to Notice
More information24-Week CNTO1275PSA3001 Clinical Study Report
24-Week CNTO1275PSA3001 Clinical Study Report SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, Inc Ustekinumab
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION TOFACITINIB (Xeljanz Pfizer Canada Inc.) Indication: Rheumatoid Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that tofacitinib be listed, in combination
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationPsA. SIMPONI (golimumab) Rheumatoid arthritis. Psoriatic arthritis. Ankylosing spondylitis EFFICACY EFFICACY EFFICACY. QoL. QoL.
RA Rheumatoid arthritis PsA Psoriatic arthritis AS Ankylosing spondylitis EFFICACY EFFICACY EFFICACY QoL QoL QoL SAFETY SAFETY SAFETY EXPERIENCE EXPERIENCE EXPERIENCE SUMMARY SUMMARY SUMMARY Copyright
More informationustekinumab 130mg concentrate for solution for infusion and 90mg solution for injection (Stelara ) SMC No. (1250/17) Janssen-Cilag Ltd
ustekinumab 130mg concentrate for solution for infusion and 90mg solution for injection (Stelara ) SMC No. (1250/17) Janssen-Cilag Ltd 09 June 2017 The Scottish Medicines Consortium (SMC) has completed
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationSTELARA DATA SHEET NAME OF THE MEDICINE DESCRIPTION V L C L V H C H 1 C H 2 C H 3. Fab. F(ab)' 2. hinge
DATA SHEET NAME OF THE MEDICINE Ustekinumab (rmc). CAS Registry Number: 815610-63-0. DESCRIPTION (ustekinumab) is a human IgG1kappa monoclonal antibody with an approximate molecular weight of 148,600 daltons.
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationDr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,
More information